RADVAX for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 15 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 15 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 09 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.